In vivo platelet activation is associated with increased plasma levels of vascular endothelial growth factor

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Thrombosis and Haemostasis

• Publication date

  2003-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1046/j.1538-7836.2003.t01-3-00115.xPMID 12871428
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Low specificity of the 125I-fibrinogen uptake test for the diagnosis of deep vein thrombosis in patients with erysipelas of the leg.

  2009cited by this paper
• Venous thromboembolism in patients undergoing laparoscopic and arthroscopic surgery and in leg casts.

  2002cited by this paper
• Advances in the therapy of von Willebrand disease

  2002cited by this paper
• Factor XIII – Circulating Levels and the Val34Leu Polymorphism in the Healthy Male Relatives of Patients with Severe Coronary Artery Disease

  2002cited by this paper
• Common bacterial skin infections.

  2002cited by this paper
• Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery: A randomized trial of prophylaxis with low--molecular weight heparin.

  2002cited by this paper
• Factor XIII A‐subunit concentration predicts outcome in stroke subjects and vascular outcome in healthy, middle‐aged men

  2002cited by this paper
• Vascular endothelial growth factor enhances atherosclerotic plaque progression

  2001cited by this paper
• Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): Results of a randomized controlled trial.

  2001cited by this paper
• Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate.

  2001cited by this paper
• Incidence, Natural History and Risk Factors of Deep Vein Thrombosis in Elective Knee Arthroscopy

  2001cited by this paper
• Coagulation Factor XIII and Cardiovascular Disease in UK Asian Patients Undergoing Coronary Angiography

  2001cited by this paper
• Survey of the use of thromboprophylaxis in laparoscopic surgery in Denmark

  2001cited by this paper
• Coagulation Factor XIII Levels in UK Asian Subjects with Type 2 Diabetes mellitus and Coronary Artery Disease

  2001cited by this paper
• Factor XIII Activity and Antigen Levels in Patients with Coronary Artery Disease

  2001cited by this paper
• Deep Venous Thrombosis Prophylaxis is not Indicated for Laparoscopic Cholecystectomy

  2001cited by this paper
• Existe-t-il une place pour les anticoagulants dans le traitement de l’érysipèle?

  2000cited by this paper
• The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction.

  2000cited by this paper
• Non-invasive diagnosis of venous thromboembolism in outpatients.

  1999cited by this paper
• Association of a common polymorphism in the factor XIII gene with venous thrombosis.

  1999cited by this paper
• In vitro release of vascular endothelial growth factor during platelet aggregation.

  1998cited by this paper
• Association of a Common Polymorphism in the Factor XIII Gene with Myocardial Infarction

  1998cited by this paper
• Incidence of venographically proved deep vein thrombosis after knee arthroscopy.

  1998cited by this paper
• P-Selectin and platelet clearance.

  1998cited by this paper
• Thromboembolic complications after arthroscopic knee surgery. Incidence and risk factors in 101 patients.

  1998cited by this paper
• Thromboembolism prophylaxis during laparoscopic cholecystectomy

  1997cited by this paper
• A comparison of compression ultrasound with color Doppler ultrasound for the diagnosis of symptomless postoperative deep vein thrombosis.

  1997cited by this paper
• Value of assessment of pretest probability of deep-vein thrombosis in clinical management.

  1997cited by this paper
• Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets.

  1997cited by this paper
• Streptococcal infections of skin and soft tissues.

  1996cited by this paper
• In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function.

  1996cited by this paper
• Erysipelas: clinical and bacteriologic spectrum and serological aspects.

  1996cited by this paper
• Incidence of deep vein thrombosis after arthroscopic knee surgery: a prospective study.

  1995cited by this paper
• Postoperative hypercoagulability and deep-vein thrombosis after laparoscopic cholecystectomy

  1995cited by this paper
• Limitations of compression ultrasound for the detection of symptomless postoperative deep vein thrombosis.

  1994cited by this paper
• Day-only admission for varicose vein surgery.

  1994cited by this paper
• Characterization of GMP-140 (P-selectin) as a circulating plasma protein

  1992cited by this paper
• Deep vein thrombosis after elective knee surgery. An incidence study in 312 patients.

  1989cited by this paper
• Conformational changes in von Willebrand's factor protein: Effects on the binding of factor VIII‐coagulant

  1986cited by this paper
• Prophylaxis of Venous Thromboembolism

  1986cited by this paper
• Von Willebrand factor in the vessel wall mediates platelet adherence.

  1985cited by this paper
• Binding of factor VIII-von Willebrand factor to human arterial subendothelium precedes increased platelet adhesion and enhances platelet spreading.

  1981cited by this paper
• Clinical Validity of a Negative Venogram in Patients with Clinically Suspected Venous Thrombosis

  1981cited by this paper
• Factor VIII-related properties in platelets from patients with von Willebrand's disease.

  1978cited by this paper
• Von Willebrand's Disease

  1964cited by this paper

• Release of α-granule contents during platelet activation

  2021cites this paper
• Expression of vascular infarction-related molecules after anti-vascular endothelium growth factor treatment for diabetic macular edema

  2019cites this paper
• Running Head: Platelet-derived TSP-1 may be a biomarker

  2017cites this paper
• VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients

  2016cites this paper
• Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis.

  2010cites this paper
• , potential biomarker of angiogenesis Platelet-derived thrombospondin-1 is a critical negative regulator and

  2010cites this paper
• Thromboembolic events in patients treated with anti-angiogenic drugs.

  2009cites this paper
• In vivo platelet activation is responsible for enhanced vascular endothelial growth factor levels in hypertensive patients.

  2008cites this paper
• VASCULARENDOTHELIALGROWTHFACTOR, LIPOPOROTEIN-ASSOCIATED PHOSPHOLIPASEA2, SP-SELECTINANDANTIPHOSPHOLIPIDANTIBODIES, BIOLOGICALMARKERSWITHPROGNOSTICVALUEINPULMONARY HYPERTENSIONASSOCIATEDWITHCHRONICOBSTRUCTIVEPULMONARY DISEASEANDSYSTEMICLUPUSERITHEMATOSUS

  2007cites this paper
• Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus.

  2007cites this paper
• –455G/A β-fibrinogen gene polymorphism, factor V Leiden, prothrombin G20210A mutation and MTHFR C677T, and placental vascular complications

  2004cites this paper
• VASCULAR ENDOTHELIAL GROWTH FACTOR , LIPOPOROTEIN-ASSOCIATED PHOSPHOLIPASE A 2 , SP-SELECTIN AND ANTIPHOSPHOLIPID ANTIBODIES , BIOLOGICAL MARKERS WITH PROGNOSTIC VALUE IN PULMONARY HYPERTENSION ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND SYSTEMIC LUPUS

  year unknowncites this paper